Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
By M. Letko, A. Marzi, V. Munster. 2020
2,875 citations recorded by the source corpus.
Over the past 20 years, several coronaviruses have crossed the species barrier into humans, causing outbreaks of severe, and often fatal, respiratory illness. Since SARS-CoV was first identified in animal markets, global viromics projects have discovered thousands of coronavirus sequences in diverse animals and geographic regions. Unfortunately, there are few tools available to functionally test these viruses for their ability to infect humans, which has severely hampered efforts to predict the next zoonotic viral outbreak. Here, we developed an approach to rapidly screen lineage B betacoronaviruses, such as SARS-CoV and the recent SARS-CoV-2, for receptor usage and their ability to infect cell types from different species. We show that host protease processing during viral entry is a significant barrier for several lineage B viruses and that bypassing this barrier allows several lineage B viruses to enter human cells through an unknown receptor. We also demonstrate how different lineage B viruses can recombine to gain entry into human cells, and confirm that human ACE2 is the receptor for the recently emerging SARS-CoV-2. This study describes the development of an approach to rapidly screen lineage B betacoronaviruses, such as SARS-CoV and the recently emerged SARS-CoV-2, for receptor usage and their ability to infect cell types from different species. Using it, they confirm human ACE2 as the receptor for SARs-CoV-2 and show that host protease processing during viral entry is a significant barrier for viral entry.
Subfields: Animal Science and Zoology, Infectious Diseases
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Animal Science and Zoology
In Infectious Diseases
- D. Veesler
- A. Walls
- M. A. Tortorici
- F. Krammer
- Young-Jun Park
- Ian A. Wilson
- L. Garcia
- Andrew T. McGuire
Citations in the corpus
- Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 (2020, neutral): “Both SARS-CoV-2 S and SARS-CoV S bind to angiotensin-converting enzyme 2 (ACE2), which serves as entry receptor (Hoffmann et al., 2020; Letko et al., 2020; Li et al., 2003; Walls et al., 2020; Wrapp et al., 2020; Zhou et al., 2020c).”
- Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding (2020, neutral): “Relative binding is Δlog10(KD,app) measured in the current study; relative cellular entry is infection of ACE2-expressing cells by VSV pseudotyped with spike containing the indicated RBD, reported by Letko et al. (Letko et al., 2020) in arbitrary luciferase units relative to SARS-CoV-1 RBD; n.d. ind”
- COVID-19 and diabetes: Knowledge in progress (2020, neutral): “[50] Letko Michael, Marzi Andrea, Munster Vincent.”
- Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding (2020, positive): “The panel of RBD homologs from other sarbecovirus strains all expressed well but exhibited a wide range of ACE2-binding affinities (Figures 2C and 2D; Table S1), as expected since only some are derived from viruses that can enter cells using human ACE2 (Letko et al., 2020).”
- SARS-CoV-2 Vaccines: Status Report (2020, methodology): “Initial work showed that it can use angiotensin-converting enzyme 2 (ACE2) from bats, civet cats, swine, cats, ferrets, non-human primates (NHPs), and humans as a receptor (Letko et al., 2020;Wan et al., 2020; Zhou et al., 2020).”
- Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19 (2020, background): “28, 29 Following entry of the virus into the host cell, the virus complex is then translocated to the endosome, where endosomal acid proteases cleave the S protein mediating membrane fusion.”
- Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 (2020, neutral): “Phylogenetic analysis of SARS-CoV-2 demonstrated that this virus belongs to lineage B of the betacoronavirus genus (Chan et al., 2020; Letko et al., 2020).”
- Immune Response, Inflammation, and the Clinical Spectrum of COVID-19 (2020, background): “RBDACE2 binding induces conformational changes on S that lead to cleavage of S1 and S2, a process mediated by the serine protease TMPRSS2, allowing S2 to facilitate the fusion of the virus envelope with the cell membrane, thus permitting viral RNA entrance into the cytoplasm of the target cells (23,”
- Title: Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice (2020, neutral): “From 29 RBDs that were classified into distinct clades (clades 1, 2, 1/2, and 3) (38), we identified diverse RBDs from SARS-CoV, WIV1, and SHC014 (clade 1), SARS-CoV-2 (clade 1/2), Rs4081, Yunnan 2011 (Yun11), and Rf1 (clade 2), and BM48-31 (clade 3), of which SARS-CoV-2 and SARS-CoV are human coron”
- Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology (2020, positive): “…receptor-binding domain or RBD) binds to angiotensin-converting enzyme 2 (ACE2), which serves as an entry receptor (Hoffmann et al., 2020b; Letko et al., 2020; Walls et al., 2020; Wrapp et al., 2020; Zhou et al., 2020a), and the molecular details of attachment have been recently unveiled…”
- Site-specific glycan analysis of the SARS-CoV-2 spike (2020, background): “SARS-CoV-2 utilizes an extensively glycosylated spike (S) protein that protrudes from the viral surface to bind to angiotensin-converting enzyme 2 (ACE2) to mediate host-cell entry (3).”
- Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review (2020, background): “Apart from ORF1a and ORF1b, other ORFs encode for structural proteins, including spike, membrane, envelope, and nucleocapsid proteins and accessory proteic chains [14,15].”